L Gallicchio1, R MacDonald, B Wood, E Rushovich, K J Helzlsouer. 1. The Prevention and Research Center, Weinberg Center for Women's Health & Medicine, Mercy Medical Center, 227 St. Paul Place, Baltimore, MD 21202, USA.
Abstract
OBJECTIVES: To examine self-reported menopausal-type symptoms among breast cancer patients on aromatase inhibitors (AIs) compared to women of the same age who had not been diagnosed with cancer, and to determine whether the percentage of breast cancer patients experiencing these symptoms changed over the first 6 months of AI treatment. METHODS: Data from a 6-month cohort study of 100 breast cancer patients initiating AI therapy and of 200 women of a similar age without a history of cancer were analyzed. At baseline (prior to the initiation of AI therapy among the breast cancer patients), 3 months, and 6 months, a comprehensive questionnaire was administered to participants that ascertained data on the experiencing of specific menopausal-type symptoms. RESULTS: The data showed statistically significant increases in the prevalence of certain symptoms from baseline to either follow-up point among the breast cancer patients; these symptoms included hot flushes, night sweats, pain during intercourse, hair loss, forgetfulness, depression, difficulty falling asleep, and interrupted sleep. Additionally, breast cancer patients were more likely than the women in the comparison group to report the new onset of many of these same symptoms during the follow-up time period. CONCLUSIONS: Because bothersome symptoms and side-effects are a major reason for discontinuation and non-adherence to treatment, symptoms should be monitored and addressed by oncologists so that the breast cancer patient can maintain her quality of life and remain adherent to the treatment schedule.
OBJECTIVES: To examine self-reported menopausal-type symptoms among breast cancerpatients on aromatase inhibitors (AIs) compared to women of the same age who had not been diagnosed with cancer, and to determine whether the percentage of breast cancerpatients experiencing these symptoms changed over the first 6 months of AI treatment. METHODS: Data from a 6-month cohort study of 100 breast cancerpatients initiating AI therapy and of 200 women of a similar age without a history of cancer were analyzed. At baseline (prior to the initiation of AI therapy among the breast cancerpatients), 3 months, and 6 months, a comprehensive questionnaire was administered to participants that ascertained data on the experiencing of specific menopausal-type symptoms. RESULTS: The data showed statistically significant increases in the prevalence of certain symptoms from baseline to either follow-up point among the breast cancerpatients; these symptoms included hot flushes, night sweats, pain during intercourse, hair loss, forgetfulness, depression, difficulty falling asleep, and interrupted sleep. Additionally, breast cancerpatients were more likely than the women in the comparison group to report the new onset of many of these same symptoms during the follow-up time period. CONCLUSIONS: Because bothersome symptoms and side-effects are a major reason for discontinuation and non-adherence to treatment, symptoms should be monitored and addressed by oncologists so that the breast cancerpatient can maintain her quality of life and remain adherent to the treatment schedule.
Authors: Rebecca A Shelby; Caroline S Dorfman; Hayden B Bosworth; Francis Keefe; Linda Sutton; Lynda Owen; Leonor Corsino; Alaattin Erkanli; Shelby D Reed; Sarah S Arthur; Tamara Somers; Nadine Barrett; Scott Huettel; Juan Marcos Gonzalez; Gretchen Kimmick Journal: Contemp Clin Trials Date: 2018-11-22 Impact factor: 2.226
Authors: Caitlin C Murphy; L Kay Bartholomew; Melissa Y Carpentier; Shirley M Bluethmann; Sally W Vernon Journal: Breast Cancer Res Treat Date: 2012-06-12 Impact factor: 4.872
Authors: Julie L Otte; Janet S Carpenter; Shalini Manchanda; Kevin L Rand; Todd C Skaar; Michael Weaver; Yelena Chernyak; Xin Zhong; Christele Igega; Carol Landis Journal: Cancer Med Date: 2014-11-30 Impact factor: 4.452
Authors: Susan Grayson; Susan Sereika; Caroline Harpel; Emilia Diego; Jennifer G Steiman; Priscilla F McAuliffe; Susan Wesmiller Journal: Support Care Cancer Date: 2021-07-10 Impact factor: 3.603